Recall costs drag down Cochlear FY12 profit
07 August, 2012 by Dylan Bushell-EmblingCochlear Limited (ASX:COH) has reported a 68% slump in FY12 profit to $56.8 million due to hefty costs associated with the voluntary recall of its Nucleus Cl500 implants.
Universal Biosensors slashes 1H loss in half
07 August, 2012 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) more than halved its losses for the first half of 2012, on the back of a 133% increase in revenue.
Vic Gov listens to concern on clinical trial insurance
07 August, 2012 by AusBiotechCognisant of industry concern, the Victorian Managed Insurance Authority (VMIA) has chosen not to increase the insurance requirements for commercial sponsors of human clinical trials in Victoria, which was intended to take effect from 1 July 2012.
ResMed stock bounce on record quarterly profit
06 August, 2012 by Dylan Bushell-EmblingResMed (ASX:RMD) shares up following 12% increase in FY12 profit, on the back of another quarter of record revenue and net income.
Sirtex to triple US manufacturing capacity
03 August, 2012 by Dylan Bushell-EmblingSirtex (ASX:SIR) will spend $4m over the next 18 months to expand threefold its US manufacturing capacity for SIR-Spheres doses.
Brian McNamee to step down from CSL next July
03 August, 2012 by Dylan Bushell-EmblingCSL's (ASX:CSL) CEO for the last 22 years, Dr Brian McNamee, will hand the reins to successor Paul Perrault in July 2013.
AusBiotech responds to NSW’s draft Manufacturing Industry Action Plan
02 August, 2012 by AusBiotechAusBiotech has undertaken extensive consultation with its NSW medical technology members through an open consultation forum and private meetings and responded to the draft NSW Manufacturing Industry Action Plan.
Kavanagh lends marketing experience to Nanosonics’ board
02 August, 2012 by Dylan Bushell-EmblingNewly-appointed Nanosonics (ASX:NAN) director Michael Kavanagh will offer his experience introducing new products into the healthcare market in order to see the company succeed on the world stage.
Start-up gets backing for stroke rehab tool
02 August, 2012 by Dylan Bushell-EmblingUniQuest's latest start-up SMART Arm has secured investment support to launch its eponymous product, a device for improving arm function in stroke victims.
Bioniche developing synthetic cow fertility product
01 August, 2012 by Dylan Bushell-EmblingBioniche Life Sciences (ASX:BNC) could be on the road to developing the world's first entirely synthetic FSH product for increasing fertility rates in cows, proof-of-concept stage data suggests.
pSivida signs first evaluation deal for eye treatment
31 July, 2012 by Dylan Bushell-EmblingpSivida (ASX:PVA) has scored another deal this week, with a major biopharmaceutical company signing up to evaluate the company's Tethadur opthalmic technology.
New ASX listing rules to support maturing biotechs
31 July, 2012 by AusBiotechAs part of a range of initiatives to improve the competitiveness of Australia’s financial markets, the Australian Securities Exchange (ASX) has finalised new listing rules to help make it easier for small to medium size companies to raise capital for investment.
Alchemia set to receive share of profits from fondaparinux sales
31 July, 2012 by Dylan Bushell-EmblingAlchemia Limited (ASX:ACL) is due to start receiving a share of the profits from US sales of its anticoagulant product, generic fondaparinux.
CathRx borrows to cover short term expenses
31 July, 2012 by Tim DeanCathRx (ASX:CXD) has taken a $1m loan to cover short term expenses until it can finalise a more substantial capital raising, due within a couple of months.
Osprey Medical packs $18m cash after IPO
30 July, 2012 by Dylan Bushell-EmblingMedical device company Osprey Medical (ASX:OSP) is still cashed up from its 20 million IPO on the ASX, despite recording a cash outflow for the June quarter of $1.4 million.
